This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nasjletti, A. Search for Related Content PubMed PubMed Citation Articles by Nasjletti, A.

(Hypertension. 1998;31:194.)
© 1998 American Heart Association, Inc.

Arthur C. Corcoran Memorial Lecture

The Role of Eicosanoids in Angiotensin-Dependent Hypertension

Alberto Nasjletti, MD

From the Department of Pharmacology, New York Medical College, Valhalla, New York, NY.

Correspondence to Alberto Nasjletti, MD, Department of Pharmacology, New York Medical College, Valhalla, NY 10595

Many eicosanoids produced in vascular and renal structures are endowed with the ability to influence vascular and renal mechanisms of blood pressure regulation. Eicosanoids subserve both prohypertensive and antihypertensive mechanisms. The development of angiotensin-dependent hypertension in rats is accompanied by increased vascular production of thromboxane A₂ (TXA₂) and of lipoxygenase-derived products with the ability to inhibit prostacyclin synthase. As a result of these abnormalities, the activity of pressor mechanisms mediated by TXA₂ and/or prostaglandin (PG) H₂ is increased. The cancellation of TXA₂- and/or of PGH₂-mediated pressor mechanisms, after treatment with thromboxane synthase inhibitors or TXA₂/PGH₂ receptor blockers, lowers blood pressure in rats with angiotensin-dependent hypertension. Inhibitors of lipoxygenase also lower blood pressure in such animals, in part by decreasing the synthesis of lipoxygenase-derived inhibitors of prostacyclin synthase. Thus, the vasodepressor effect of these agents is accompanied by increased vascular formation of PGI₂ and can be prevented by cyclooxygenase inhibitors. Cyclooxygenase-derived eicosanoids, PGE₂ and PGI₂, also subserve antihypertensive mechanisms in angiotensin-dependent models of hypertension. The level of blood pressure in such models of hypertension reflects, in part, the interplay among prohypertensive and antihypertensive functions subserved by cyclooxygenase- and lipoxygenase-derived eicosanoids.

Key Words: hypertension • angiotensin II • eicosanoids • cyclooxygenase • lipoxygenase

Abbreviations: HETE = hydroxyeicosatetraenoic acid • HPETE = hydroperoxyeicosatextraenoic acid • PG = prostaglandin • TX = thromboxane

This article has been cited by other articles:

				H. Francois, N. Makhanova, P. Ruiz, J. Ellison, L. Mao, H. A. Rockman, and T. M. Coffman A role for the thromboxane receptor in L-NAME hypertension Am J Physiol Renal Physiol, October 1, 2008; 295(4): F1096 - F1102. [Abstract] [Full Text] [PDF]

				C. Zeng, I. Armando, Y. Luo, G. M. Eisner, R. A. Felder, and P. A. Jose Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H551 - H569. [Abstract] [Full Text] [PDF]

				Z. Qi, H. Cai, J. D. Morrow, and M. D. Breyer Differentiation of Cyclooxygenase 1- and 2-Derived Prostanoids in Mouse Kidney and Aorta Hypertension, August 1, 2006; 48(2): 323 - 328. [Abstract] [Full Text] [PDF]

				H. A. Kadi, H. Nasrat, and F. B. Pipkin A prospective, longitudinal study of the renin-angiotensin system, prostacyclin and thromboxane in the first trimester of normal human pregnancy: association with birthweight Hum. Reprod., November 1, 2005; 20(11): 3157 - 3162. [Abstract] [Full Text] [PDF]

				C. Zeng, H. Sanada, H. Watanabe, G. M. Eisner, R. A. Felder, and P. A. Jose Functional genomics of the dopaminergic system in hypertension Physiol Genomics, November 17, 2004; 19(3): 233 - 246. [Abstract] [Full Text] [PDF]

				H. Francois, K. Athirakul, L. Mao, H. Rockman, and T. M. Coffman Role for Thromboxane Receptors in Angiotensin-II-Induced Hypertension Hypertension, February 1, 2004; 43(2): 364 - 369. [Abstract] [Full Text] [PDF]

				P. Liu, D. A. Misurski, and V. Gopalakrishnan Cysteinyl leukotriene-dependent [Ca2+]i responses to angiotensin II in cardiomyocytes Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1269 - H1276. [Abstract] [Full Text] [PDF]

				F. J He and G. A MacGregor Review: Salt, blood pressure and the renin-angiotensin system Journal of Renin-Angiotensin-Aldosterone System, March 1, 2003; 4(1): 11 - 16. [Abstract] [PDF]

				Y. Mukai, H. Shimokawa, M. Higashi, K. Morikawa, T. Matoba, J. Hiroki, I. Kunihiro, H. M.A. Talukder, and A. Takeshita Inhibition of Renin-Angiotensin System Ameliorates Endothelial Dysfunction Associated With Aging in Rats Arterioscler Thromb Vasc Biol, September 1, 2002; 22(9): 1445 - 1450. [Abstract] [Full Text] [PDF]

				C. Berry, R. Touyz, A. F. Dominiczak, R. C. Webb, and D. G. Johns Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2337 - H2365. [Abstract] [Full Text] [PDF]

				S. T. Davidge Prostaglandin H Synthase and Vascular Function Circ. Res., October 12, 2001; 89(8): 650 - 660. [Abstract] [Full Text] [PDF]

				F. J. He, N. D. Markandu, and G. A. MacGregor Importance of the Renin System for Determining Blood Pressure Fall With Acute Salt Restriction in Hypertensive and Normotensive Whites Hypertension, September 1, 2001; 38(3): 321 - 325. [Abstract] [Full Text] [PDF]

				E. K. Jackson and W. A. Herzer Regional Vascular Selectivity of Angiotensin II J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 736 - 745. [Abstract] [Full Text]

				L. P. Audoly, X. Ruan, V. A. Wagner, J. L. Goulet, S. L. Tilley, B. H. Koller, T. M. Coffman, and W. J. Arendshorst Role of EP2 and EP3 PGE2 receptors in control of murine renal hemodynamics Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H327 - H333. [Abstract] [Full Text] [PDF]

				F. Stanke-Labesque, P. Devillier, S. Veitl, F. Caron, J.-L. Cracowski, and G. Bessard Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats Cardiovasc Res, January 1, 2001; 49(1): 152 - 160. [Abstract] [Full Text] [PDF]

				Z. Ungvari and A. Koller Endothelin and Prostaglandin H2/Thromboxane A2 Enhance Myogenic Constriction in Hypertension by Increasing Ca2+ Sensitivity of Arteriolar Smooth Muscle Hypertension, November 1, 2000; 36(5): 856 - 861. [Abstract] [Full Text] [PDF]

				H. Honeck, V. Gross, B. Erdmann, E. Kargel, R. Neunaber, A. F. Milia, W. Schneider, F. C. Luft, and W.-H. Schunck Cytochrome P450-Dependent Renal Arachidonic Acid Metabolism in Desoxycorticosterone Acetate-Salt Hypertensive Mice Hypertension, October 1, 2000; 36(4): 610 - 616. [Abstract] [Full Text] [PDF]

				K. D. Croft, J. C. McGiff, A. Sanchez-Mendoza, and M. A. Carroll Angiotensin II releases 20-HETE from rat renal microvessels Am J Physiol Renal Physiol, September 1, 2000; 279(3): F544 - F551. [Abstract] [Full Text] [PDF]

				C. G. Schnackenberg, W. J. Welch, and C. S. Wilcox TP receptor-mediated vasoconstriction in microperfused afferent arterioles: roles of O2- and NO Am J Physiol Renal Physiol, August 1, 2000; 279(2): F302 - F308. [Abstract] [Full Text] [PDF]

				L. P. Audoly, S. L. Tilley, J. Goulet, M. Key, M. Nguyen, J. L. Stock, J. D. McNeish, B. H. Koller, and T. M. Coffman Identification of specific EP receptors responsible for the hemodynamic effects of PGE2 Am J Physiol Heart Circ Physiol, September 1, 1999; 277(3): H924 - H930. [Abstract] [Full Text] [PDF]